U.S. Hemophilia Treatment Market 规模与份额分析 - 成长趋势与预测 (2024 - 2031)
U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of U.S. Hemophilia Treatment Market
在美国血友病治疗市场运营的主要玩家包括武田制药有限公司,. Sanofi Octaphama AG、瑞典孤儿Biovitrium AB、Baxter国际公司、Biogen Inc.、Bayer AG、CSL Behring、Ferring B.V.、Pfize公司、Kedrion、Novo Nordisk A/S、Grifols S.A.、Sangamo治疗技术公司和Spark治疗技术公司。
U.S. Hemophilia Treatment Market Leaders
- 武田药 有限公司
- 萨诺菲·奥克塔帕马股份有限公司
- 瑞典孤儿 Biovitrium AB
- 巴克斯特国际 联合国
- 生物基因股份有限公司.
*Disclaimer: Major players are listed in no particular order.
U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023
U.S. Hemophilia Treatment Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights